PURPOSE: Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to identify the molecular characteristics of CHEK2-driven BCs. METHODS: Loss of heterozygosity (LOH) for the remaining CHEK2 allele was examined in 50 CHEK2-driven BCs using allele-specific PCR assays for the germline mutations and analysis of surrounding single-nucleotide polymorphisms (SNPs). Paired tumor and normal DNA samples from 25 cases were subjected to next-generation sequencing analysis. RESULTS: CHEK2 LOH was detected in 28/50 (56%) BCs. LOH involved the wild-type allele in 24 BCs, mutant CHEK2 copy was deleted in 3 carcinomas, while in one case the origin of the deleted allele could not be identified. Somatic PIK3CA and TP53 mutations were present in 13/25 (52%) and 4/25 (16%) tumors, respectively. Genomic features of homologous recombination deficiency (HRD), including the HRD score ≥ 42, the predominance of BRCA-related mutational signature 3, and the high proportion of long (≥ 5 bp) indels, were observed only in 1/20 (5%) BC analyzed for chromosomal instability. Tumors with the deleted wild-type CHEK2 allele differed from LOH-negative cases by elevated HRD scores (median 23 vs. 7, p = 0.010) and higher numbers of chromosomal segments affected by copy number aberrations (p = 0.008). CONCLUSION: Somatic loss of the wild-type CHEK2 allele is observed in approximately half of CHEK2-driven BCs. Tumors without CHEK2 LOH are chromosomally stable. BCs with LOH demonstrate some signs of chromosomal instability; however, its degree is significantly lower as compared to BRCA1/2-associated cancers.
PURPOSE: Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to identify the molecular characteristics of CHEK2-driven BCs. METHODS: Loss of heterozygosity (LOH) for the remaining CHEK2 allele was examined in 50 CHEK2-driven BCs using allele-specific PCR assays for the germline mutations and analysis of surrounding single-nucleotide polymorphisms (SNPs). Paired tumor and normal DNA samples from 25 cases were subjected to next-generation sequencing analysis. RESULTS: CHEK2 LOH was detected in 28/50 (56%) BCs. LOH involved the wild-type allele in 24 BCs, mutant CHEK2 copy was deleted in 3 carcinomas, while in one case the origin of the deleted allele could not be identified. Somatic PIK3CA and TP53 mutations were present in 13/25 (52%) and 4/25 (16%) tumors, respectively. Genomic features of homologous recombination deficiency (HRD), including the HRD score ≥ 42, the predominance of BRCA-related mutational signature 3, and the high proportion of long (≥ 5 bp) indels, were observed only in 1/20 (5%) BC analyzed for chromosomal instability. Tumors with the deleted wild-type CHEK2 allele differed from LOH-negative cases by elevated HRD scores (median 23 vs. 7, p = 0.010) and higher numbers of chromosomal segments affected by copy number aberrations (p = 0.008). CONCLUSION: Somatic loss of the wild-type CHEK2 allele is observed in approximately half of CHEK2-driven BCs. Tumors without CHEK2 LOH are chromosomally stable. BCs with LOH demonstrate some signs of chromosomal instability; however, its degree is significantly lower as compared to BRCA1/2-associated cancers.
Authors: Cezary Cybulski; Dominika Wokołorczyk; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Bohdan Górski; Tadeusz Debniak; Bartłomiej Masojć; Anna Jakubowska; Thierry van de Wetering; Steven A Narod; Jan Lubiński Journal: Breast Cancer Res Treat Date: 2006-08-08 Impact factor: 4.872
Authors: Jord H A Nagel; Justine K Peeters; Marcel Smid; Anieta M Sieuwerts; Marijke Wasielewski; Vanja de Weerd; Anita M A C Trapman-Jansen; Ans van den Ouweland; Hennie Brüggenwirth; Wilfred F J van I Jcken; Jan G M Klijn; Peter J van der Spek; John A Foekens; John W M Martens; Mieke Schutte; Hanne Meijers-Heijboer Journal: Breast Cancer Res Treat Date: 2011-05-26 Impact factor: 4.872
Authors: Pawel Domagala; Dominika Wokolorczyk; Cezary Cybulski; Tomasz Huzarski; Jan Lubinski; Wenancjusz Domagala Journal: Breast Cancer Res Treat Date: 2011-06-24 Impact factor: 4.872
Authors: C Cybulski; D Wokołorczyk; T Huzarski; T Byrski; J Gronwald; B Górski; T Debniak; B Masojć; A Jakubowska; B Gliniewicz; A Sikorski; M Stawicka; D Godlewski; Z Kwias; A Antczak; K Krajka; W Lauer; M Sosnowski; P Sikorska-Radek; K Bar; R Klijer; R Zdrojowy; B Małkiewicz; A Borkowski; T Borkowski; M Szwiec; S A Narod; J Lubiński Journal: J Med Genet Date: 2006-11 Impact factor: 6.318
Authors: Mieke Schutte; Sheila Seal; Rita Barfoot; Hanne Meijers-Heijboer; Marijke Wasielewski; D Gareth Evans; Diana Eccles; Carel Meijers; Frans Lohman; Jan Klijn; Ans van den Ouweland; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Douglas F Easton; Michael R Stratton; Nazneen Rahman Journal: Am J Hum Genet Date: 2003-02-27 Impact factor: 11.025
Authors: Cezary Cybulski; Tomasz Huzarski; Bohdan Górski; Bartłomiej Masojć; Marek Mierzejewski; Tadeusz Debniak; Bartłomiej Gliniewicz; Joanna Matyjasik; Elzbieta Złowocka; Grzegorz Kurzawski; Andrzej Sikorski; Michał Posmyk; Marek Szwiec; Ryszard Czajka; Steven A Narod; Jan Lubiński Journal: Cancer Res Date: 2004-04-15 Impact factor: 12.701
Authors: Anna P Sokolenko; Natalia Bogdanova; Wojciech Kluzniak; Elena V Preobrazhenskaya; Ekatherina S Kuligina; Aglaya G Iyevleva; Svetlana N Aleksakhina; Natalia V Mitiushkina; Tatiana V Gorodnova; Alexandr A Bessonov; Alexandr V Togo; Jan Lubiński; Cezary Cybulski; Anna Jakubowska; Thilo Dörk; Evgeny N Imyanitov Journal: Breast Cancer Res Treat Date: 2014-05-07 Impact factor: 4.872
Authors: C Cybulski; T Huzarski; T Byrski; J Gronwald; T Debniak; A Jakubowska; B Górski; D Wokołorczyk; B Masojć; S A Narod; J Lubiński Journal: Clin Genet Date: 2008-11-17 Impact factor: 4.438
Authors: Marjanka K Schmidt; Frans Hogervorst; Richard van Hien; Sten Cornelissen; Annegien Broeks; Muriel A Adank; Hanne Meijers; Quinten Waisfisz; Antoinette Hollestelle; Mieke Schutte; Ans van den Ouweland; Maartje Hooning; Irene L Andrulis; Hoda Anton-Culver; Natalia N Antonenkova; Antonis C Antoniou; Volker Arndt; Marina Bermisheva; Natalia V Bogdanova; Manjeet K Bolla; Hiltrud Brauch; Hermann Brenner; Thomas Brüning; Barbara Burwinkel; Jenny Chang-Claude; Georgia Chenevix-Trench; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Alison M Dunning; Peter A Fasching; Jonine Figueroa; Olivia Fletcher; Henrik Flyger; Eva Galle; Montserrat García-Closas; Graham G Giles; Lothar Haeberle; Per Hall; Peter Hillemanns; John L Hopper; Anna Jakubowska; Esther M John; Michael Jones; Elza Khusnutdinova; Julia A Knight; Veli-Matti Kosma; Vessela Kristensen; Andrew Lee; Annika Lindblom; Jan Lubinski; Arto Mannermaa; Sara Margolin; Alfons Meindl; Roger L Milne; Taru A Muranen; Polly A Newcomb; Kenneth Offit; Tjoung-Won Park-Simon; Julian Peto; Paul D P Pharoah; Mark Robson; Anja Rudolph; Elinor J Sawyer; Rita K Schmutzler; Caroline Seynaeve; Julie Soens; Melissa C Southey; Amanda B Spurdle; Harald Surowy; Anthony Swerdlow; Rob A E M Tollenaar; Ian Tomlinson; Amy Trentham-Dietz; Celine Vachon; Qin Wang; Alice S Whittemore; Argyrios Ziogas; Lizet van der Kolk; Heli Nevanlinna; Thilo Dörk; Stig Bojesen; Douglas F Easton Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544